The QLattice^® discovery engine developed by Abzu^® has accelerated scientific exploration and understanding again, this time for Peptomyc^®, a biotech focused on inhibiting the cancer-causing protein Myc. Both companies are CataloniaBio & HealthTech members.

Built on over 20 years’ research led by Laura Soucek, co-founder and Chief Executive Director of Peptomyc, Omomyc (OMO-103) is a therapeutic mini-protein which targets and inhibits the Myc oncogene. The Myc oncogene is persistently expressed in Burkitt lymphoma as well as many cervix, colon, breast, lung, pancreatic, and stomach cancers, making it one of the most sought-after drug targets in cancer. Until Peptomyc’s successful clinical trial with OMO-103, Myc was thought to be undruggable.

Peptomyc used the QLattice and Abzu’s expertise in patient stratification to reveal early predictive response-biomarkers to treatment with OMO-103 in metastatic patients. The analysis by the QLattice was conducted on a very small clinical trial of 22 patients.

“Partnering with Abzu and using the QLattice increased our ability to really take advantage of all our clinical results to find unexpected and extremely valuable data that we could have missed otherwise,” says Laura Soucek, co-founder and Chief Executive Director of Peptomyc.

“By helping scientists in understanding treatment response earlier, we’re enabling them to bring drugs to market faster,” says Marco Salvatore, Head of Target and Biomarker Discovery at Abzu. “This is an extraordinary achievement for Peptomyc, and we’re thrilled to have contributed to this scientific progress.”

OMO-103 is ready to move to a phase II study early 2023.